This is a study of the clinical effects of Regitine, a new antiadrenergic drug, the pharmacologic properties of which are similar to those of Priscoline. Thirty-four patients, whose diagnoses fall into the peripheral vascular disease group and into a miscellaneous group were first given the drug intravenously and the responses were studied with skin temperature recordings in an attempt to predict the response to therapeutic administration of Regitine. The drug was then given orally for varying periods of time, with subjective and objective evidences of response, as well as side effects being noted. The results of these observations are set forth in the paper.
R EGITINE, 2-[N-p'-tolyl-N-(m'hydroxyphenyl) -aminomethyl] -imidazoline HCl, (C-7337), is an antiadrenergic drug first developed by Marxer and Miescher in 1947. Its pharmacologic properties were reported by Meier and Yonkman' as being adrenolytic in small doses and sympatholytic in higher concentrations, the latter being reported as greater than that of Priscoline, a progenitor in the imidazoline series. These antiadrenergic properties were tested in man by Hecht, Crandall and Sam-uelsW who obtained similar results and added the assumption of local vasodilatation. Studies using direct measurement of blood flow in the femoral artery of the dog demonstrated an increase in blood flow with injections of Regitine, per se, and showed that Regitine is capable of converting the vasoconstricting effect of epinephrine into a vasodilating effect in a dosage of 0.1 to 0.15 mg. per kilogram.3 Studies. on normal students show that Regitine has an efficacy similar to Priscoline in relieving vasospasm induced by cold.4 It was felt, therefore, that clinical trial of the drug was justified and this report deals with the results of that trial conducted over an 18 months' period. one patient was 14 months, though many are continuing therapy. Most of the patients were given skin temperature studies, testing the drug intravenously, just as were the students.4 In the clinical evaluation of the drug, it was administered orally and a comparison made between the actual therapeutic response and the initial response to the intravenous injection.
MATERIAL AND METHODS Thirty-four patients were studied. They may be divided into four groups, from the point of view of diagnosis, as in table 1, in order to evaluate the results of Regitine therapy in those particular disease states. Group I is comprised of 10 patients with the diagnosis of Raynaud's disease consisting of five females and five males varying in age from 20 to 60 years. Diagnosis of Raynaud's phenomena was considered when several of the following were present: upper or lower extremity involvement, ulceration, when present, limited to tips of digits, secondary sclerodermatous changes, prominent symptoms of coldness, pallor and aching aggravated by cold, changes in nail growth, peripheral pulsations palpable, and on skin temperature study under adequate ganglionic blocking drug shows practically normal maximum temperatures as contrasted to the occlusive diseases.5 The diagnosis of primary Raynaud's disease was made when the cause was unknown. Two patients were classified as secondary Raynaud's disease in view of possible nerve trunk irritation. In one the symptoms followed myocardial infarction with subsequent shoulderhand syndrome. In the other the symptoms followed electrical burns to the hands.
Group II is composed of 14 patients with the diagnosis of arteriosclerotic peripheral vascular disease and is made up of 13 males and one female Circulation, Volume VII, April, 1953 Group III is composed of three patients with the diagnosis of thromboangiitis obliterans, all being males, aged 40, 41 and 63 years. Criteria for diagnosis in this group were: age, combined involvement of hands and feet and obliteration of peripheral pulsations. Symptoms and physical examination were otherwise essentially the same as those of arteriosclerosis; there was an absence of elevated blood cholesterol and of calcification of the blood vessels of the legs.
Group IV is composed of seven females ranging in age from 21 to 50 years with miscellaneous disorders varying from anxiety to acute pancreatitis.
Prior to administration of Regitinet orally on a therapeutic basis, an attempt was made to ascertain first the effect of the drug on the peripheral circulation of the patient by skin temperature studies. Since both vasospasm and organic occlusion are usually present in peripheral vascular disease, both the degree of occlusion and the probable degree of effectiveness of a vasodilator drug in overcoming the vasospasm can be determined by measurement of the increased skin temperature consequent to an augmented rate of delivery of heat to the skin resulting from the increase in cutaneous blood flow produced by the vasodilator drug. Records of the cutaneous temperature were made with an 8-point Leeds and Northrup micromax using iron constantin thermocouples attached to the skin with a drop * Gofman molecule (lipoprotein) determinations were done by Belmont Medical Laboratories, Inc., Belmont, Calif.
of collodion. During the study, the patients were placed in a room, the temperature of which was maintained at 19 to 20 C. The cutaneous areas to be measured were exposed to the room air and care was taken to avoid contact or close approximation of any objects which might prevent rapid circulation of air past the exposed parts. Temperatures were recorded usually over the forehead, index and fourth fingers, great and little toes, together with the room temperature. Blood flow and vasoconstriction were estimated from the relationship of the temperature of the skin to that of the room and forehead temperatures. Minimal blood flow due to maximal vasoconstriction was considered to be present when the skin temperature approximated room temperature and maximal blood flow due to maximal vasodilation when the skin temperature approximated or exceeded the forehead temperature. Regitine was injected intravenously over a 30 minute period in amounts up to 0.5 mg. per kilogram, dissolved in 250 ml. of normal saline; the total amounts given varied from 20 to 50 mg. In a further attempt to correlate the predicted response to Regitine with the actual therapeutic response, additional temperature studies were done using Etamon (TEA),: as it was felt that the fraction of effectiveness of Regitine to Etamon may represent the expected response as compared with full release of vasospasm by Etamon. These studies were carried out on 18 of the patients, the records of which are included in table 1. Etamon was injected under the same conditions as was Regitine, in the amount of 15 to 20 mg. per kilogram dissolved in 250 ml. of normal saline. The maximum dosage used was 1,732 mg. and the minimum was 645 mg.
For administration to the patients for evaluation of therapeutic response, Regitine was given orally and on an individual basis for each patient. Dosage and duration of trial are recorded in table 1, the dosage varying from as little as 30 mg. once a day to a maximum of 120 mg. four times a day, before or after meals, depending upon side effects. The maximum duration of trial was 14 months and the minimum was two weeks.
Simultaneous therapy is recorded for each patient in both for substantiation of the diagnosis and for determination of the effect upon any blood elements as previously reported by Hecht and Crandall.2 An attempt was made to obtain hemoglobin, white blood cell count and differential white blood cell determinations before and after beginning therapy with Regitine on as many patients as possible.
In order to predict the response of a given patient to the therapeutic trial with Regitine, the degrees rise in skin temperature of the part above room temperature was used as an index to the extent to which intravenous Regitine overcame the maximal vasoconstriction of the part obtained as described above. This was also a measure of the amount of vasospasm f)resent in the particular disease process, and in those in whom little or no increase in skin temperature of the affected part occurred, a similar poor response was predicted in the therapeutic trial. Figure 1 illustrates a good response in skin temperature study, and figure 2 illustrates a poor response. 
RESULTS
The responses actually obtained by the individual patients are recorded in table 1 and summarized in table 3, again on an individual and group basis. Simultaneous therapy, particularly sympthectomy, must be considered in an evaluation of results. There were five patients who underwent sympathectomy prior to use of Regitine, two during the course of treatment with Regitine, and one was done after Regitine was discontinued. It was necessary to stop Regitine on the latter patient, ANT 20211, because of an episode of acute vasomotor collapse. It is to be noted that in only one patient, MMP, 113539, of the Raynaud's disease group, was sympathectomy done and this was prior to Regitine trial. The two patients undergoing sympathectomy during their trial on Regitine were both in the arteriosclerotic group: WMD, 100950, had suffered sudden thrombus formation; poor response was predicted, of course, and subsequent amputation was necessary. The other, PEK, 114678, underwent sympathectomy because it was necessary to discontinue the drug therapy since he developed a rash while taking the drug. A good response to Regitine had been predicted from the temperature studies and had been obtained with the drug; the response to sympathectomy was satisfactory.
Correlation between the predicted and actual responses obtained was fairly good, but in several cases it was not possible to obtain a follow-up and these cannot be considered in the evaluation of the drug.
When studied by disease groups, approximately 58 pet cent of the arteriosclerotic group Mwas predicted to get fair to good response and obtained objective and/or subjective response in approximately 64 per cent. This represents a much higher percentage than would be anticipated from the nature of the disease. The Raynaud group, in whom good results might be anticipated, showed 63 per cent good or fair predicted responses, and 50 per cent showed comparable actual response. The results in the thromboanigiitis group were encouraging, though the size of the group was too small to be of any value in the evaluation of the drug in this disease. The results obtained in group IV were variable as might be anticipated from the assortment of diagnoses, and temperature studies were not obtained on four of the seven. However, a fair response was predicted for two patients of this group, GBF 3812 and NMI 5869, both of whom had chronic thrombophlebitis, but only one showed subjective improvement on Regitine therapy.
In a comparison of the vasodilating effect of Regitine and Etamon, it was found that 10 patients responded with higher average skin temperatures, in parts tested, to Etamon than to Regitine. Of this group, four were in the Raynaud group, three were in the arteriosclerotic group, two had chronic thrombophlebitis and one was in the thromboangiitis group. The response to Regitine was greater in five, and the two drugs produced essentially the same amount of skin temperature rise in three. Four of the five who showed a better response to Regitine were in the arteriosclerotic group, and of the two who obtained essentially equal responses, one was in the arteriosclerotic group, the other was in the thromboangiitis group.
Side effects noted during the therapeutic trial with Regitine are listed below in order of frequency of occurrence. The fre(quenc(.y was calculated as the percentage of patients experiencing a particular side effect, with many experiencing several of the reactions. It was necessary for seven of the patients to discontinue the drug entirely due to side effects. The total number of patients was 34.
collapse, it is difficult to explain the occurrence in these two patients and yet in none of the others. Less marked symptoms of hypotension were reported in a fairly large percentage of patients. Trapold and Warren7 have attributed reactions to Regitine to a lowering of the blood sugar level. However, the blood sugar determination done on one of the patients experiencing the vasomotor collapse was within normal limits for what was essentially a three hour postprandial level, and though there is no record of a previous determination there was no evidence of preceding hyperglycemia. The blood pressures in the two showed the typical wide pulse pressures of arteriosclerosis; the drop was predominantly systolic, suggesting a sudden reduction in stroke volume output by the heart. It is of significance that each subject had previously been taking the drug for several days before the reactions were first noted; in other words, a sensitivity seemed to have developed after prolonged use of the drug. It seems that there is no way of predicting such a reaction, or preventing it by regulating administration by meals or otherwise. However, it is easily managed by Trendelenberg position, intravenous glucose, the glucose being recommended on the basis of the earlier study referred to above, and, of course, discontinuance of the drug.
It is concluded that a trial on Regitine therapy is indicated before resorting to sympathectomy in any peripheral vascular disease as only three patients in this study underwent sympathectomy during or after Regitine therapy, and treatment has been maintained as long as fourteen months. It is a valuable adjunct after sympathectomy, and in the dose range of 30 to 60 mg. two to four times a day is tolerated with relatively few serious side effects in the majority of patients. SUMMARY 1. Regitine, a new antiadrenergic drug, has been shown to have both adrenolytic and sympatholytic properties; its ability to relieve vasospasm induced by cold being approximately equal to that of Priscoline. This paper deals with the clinical trial of Regitine, felt to be justified by previous studies.
2. Thirty-four patients were studied: 10 with Raynaud's disease, 14 with arteriosclerotic peripheral vascular disease, three with thromboangiitis obliterans and seven with miscellaneous diagnoses. 3. The patients were first tested with Regitine intravenously while skin temperatures were recorded, in order to ascertain the effect of the drug on the peripheral circulation of the patient. The response shown, and, in many cases, compared with a skin temperature study with Etamon, was used to predict the therapeutic response to Regitine. 4. Regitine was administered orally in doses ranging from 30 mg. once a day to 120 mg. four times a day. The maximum duration of trial was 14 months and the minimum was two weeks. Evaluation of the response was largely subjective, but in many, objective evidence was present.
5. Correlation between the predicted and the actual response obtained was good in the individual patient, but contradictory for the disease groups. Thus, the patients in the arteriosclerotic group appeared to obtain more benefit from the oral administration of the drug than did the Raynaud group. Results in the thromboangiitis group and in one patient with chronic thrombophlebitis were encouraging.
6. Serious side effects were few, the only reaction of any magnitude being vasomotor collapse which occurred in 2 of the 34 patients receiving the drug; however, minor side effects were noted by 62 per cent of the patients.
7. Regitine appears to be a useful adjunct to treatment of peripheral vascular diseases and is felt to be indicated prior to consideration of sympathectomy. Furthermore it is useful in subsequent treatment of cases which have undergone sympathectomy.
SUMARIo EsPANOL
Este es un estudio de los efectos clinicos de Regitine, una nueva droga anti-adren6rgica, las propiedades farmacologicas de la cual son similares a las de Priscoline. Treinta y cuatro pacientes, cuyos diagnosticos entran en el grupo de enfermedades perifero vasculares, y en un grupo miscelineo se les administro la droga intravenosamente y los resultados fueron estudiados mediante determinaciones de temperatura cutanea en un atentado a predecir el resultado terapdutico al administrar Regitine. La droga fue luego administrada oralmente por intervalos variables de tiempo con evidentes resultados subjetivos y objetivos al igual que efectos secundarios no deseables que tambi6n fueron observados. Los resultados de estas observaciones se presentan en este trabaj o.
